Exagen Q2 Revenue Jumps 14 Percent

Exagen (XGN 7.44%), a diagnostics company focused on autoimmune conditions, released its second quarter results on July 29, 2025, for the quarter ending June 30. The main headline: revenue (GAAP) beat expectations, climbing to $17.2 million due to expanding sales of its flagship AVISE CTD test, but net loss (GAAP) widened year over year to $4.4 million, and operating expenses rose. Analyst consensus predicted $16.31 million in GAAP revenue and GAAP EPS (earnings per share) of $(0.15), but the EPS (GAAP) res ...